Finance

Lists
CTNM:NASDAQ
Contineum Therapeutics Inc
13,12 $
+1,00%
(+0,13) 1D
2 қаз., 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CTNM...
Open
13,15 $
High
13,24 $
Low
12,58 $
Mkt. cap
493,59 млн
Avg. vol.
571,58 м.
Volume
1,00
52-wk high
17,78 $
52-wk low
8,60 $
EPS
-1,74 $
Shares outstanding
32,96 млн
No. of employees
51
Open
13,15 $
High
13,24 $
Low
12,58 $
Mkt. cap
493,59 млн
Avg. vol.
571,58 м.
Volume
1,00
52-wk high
17,78 $
52-wk low
8,60 $
EPS
-1,74 $
Shares outstanding
32,96 млн
No. of employees
51
News stories
From web sources and news partners
About Contineum Therapeutics Inc
CEO-
Employees51
Founded2009
Headquarters-
SectorPharmaceutical industry
Websitecontineum-tx.com
Analyst ratings
Based on 8 analysts giving stock ratings to CTNM in the past 3 months
Strong buy
Buy
7
Hold
1
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for CTNM in the last 3 months.
Highest
Current 13,12 $
28,00 $ (+113,41%)
Average
22,29 $ (+69,89%)
Lowest
17,00 $ (+29,57%)
Analyst
Recommendation
Action
Price target
Projected
Date
Paul Matteis
Stifel Nicolaus
Buy
Maintained
28,00 $
+113,4%
09/30/2026
Debanjana Chatterjee
JonesTrading
Buy
Reiterated
26,00 $
+98,2%
09/30/2026
Myles Minter
William Blair
Buy
Maintained
-
-
09/30/2026
Gaurav Maini
LifeSci Capital
Buy
Maintained
23,00 $
+75,3%
09/29/2026
Sean Laaman
Morgan Stanley
Hold
Reiterated
17,00 $
+29,6%
09/28/2026
Brian Abrahams
RBC Capital
Buy
Maintained
21,00 $
+60,1%
09/21/2026
Unknown Analyst
Leerink Partners
Buy
Maintained
22,00 $
+67,7%
09/16/2026
Charles Moore
Robert W. Baird
Buy
Maintained
19,00 $
+44,8%
09/15/2026
Last report
2026 ж. 30 шіл.
Fiscal period
Q2 2026
EPS / Est. (USD)
-0,40 $ / -0,45 $
+10,83%beat
Revenue / Est. (USD)
- / 0,00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
10,50 млн
12,00 млн
11,14 млн
11,97 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4,43 млн
5,12 млн
5,76 млн
5,45 млн
Operating expense
14,93 млн
17,12 млн
16,90 млн
17,43 млн
Total operating expenses
14,93 млн
17,12 млн
16,90 млн
17,43 млн
Operating income
-14,93 млн
-17,12 млн
-16,90 млн
-17,43 млн
Other non operating income
183,00 м.
-51,00 мың
-57,00 мың
-68,00 мың
EBT including unusual items
-12,79 млн
-15,16 млн
-14,46 млн
-15,15 млн
EBT excluding unusual items
-12,79 млн
-15,16 млн
-14,46 млн
-15,15 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-12,79 млн
-15,16 млн
-14,46 млн
-15,15 млн
Net profit margin
-
-
-
-
Earnings per share
-0,45
-0,49
-0,39
-0,40
Interest and investment income
1,96 млн
2,01 млн
2,50 млн
2,34 млн
Interest expense
-
-
-
-
Net interest expenses
1,96 млн
2,01 млн
2,50 млн
2,34 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-14,85 млн
-17,03 млн
-16,82 млн
-17,29 млн
Gain or loss from assets sale
-
-
2,00 мың
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google қолданбалары